Compare KURA & CINT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KURA | CINT |
|---|---|---|
| Founded | 2014 | 1995 |
| Country | United States | Brazil |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 765.8M | 646.9M |
| IPO Year | 2015 | 2021 |
| Metric | KURA | CINT |
|---|---|---|
| Price | $8.91 | $4.04 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 6 |
| Target Price | ★ $25.56 | $7.35 |
| AVG Volume (30 Days) | ★ 1.3M | 87.0K |
| Earning Date | 05-12-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $67,482,000.00 | N/A |
| Revenue This Year | $28.28 | $16.69 |
| Revenue Next Year | $106.37 | $11.28 |
| P/E Ratio | ★ N/A | $17.94 |
| Revenue Growth | ★ 25.24 | N/A |
| 52 Week Low | $5.45 | $3.98 |
| 52 Week High | $12.49 | $6.71 |
| Indicator | KURA | CINT |
|---|---|---|
| Relative Strength Index (RSI) | 49.98 | 29.87 |
| Support Level | $8.09 | N/A |
| Resistance Level | $10.34 | $5.01 |
| Average True Range (ATR) | 0.37 | 0.23 |
| MACD | -0.06 | -0.06 |
| Stochastic Oscillator | 26.25 | 5.32 |
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.
CI&T Inc operates as a partner in tech-integrated business solutions, helping organizations address complex challenges by integrating business approach, technology, and artificial intelligence into a single, coherent operating model. It is mainly engaged in the development of customizable software through the implementation of software solutions, including machine learning, artificial intelligence, data analytics, cloud migration and mobility technologies. The company provides technology services to various industry verticals, including Financial Services, Consumer Goods, Technology and Communications, Retail and Industrial Goods, Life Sciences, among others. The majority of the revenue is derived from providing technology services. Geographically, maximum revenue is derived from Brazil.